Apriligen
1 known investors
Apriligen develops autologous gene therapies for pediatric monogenic diseases, starting with Diamond Blackfan Anemia Syndrome. The company uses lentiviral technology to correct genetic defects by modifying patients' own cells, aiming to provide curative alternatives to traditional transplants.
Investors · 1
Competitors · 2
by search overlap
Biogen Idec4 shared keywordsBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.
Precigen3 shared keywordsPrecigen is a biopharmaceutical company developing gene and cell therapies, including PAPZIMEOS (zopapogene imadenovec-drba), an FDA-approved immunotherapy for adults with recurrent respiratory papillomatosis. The company focuses on immuno-oncology and immunotherapy treatments delivered via subcutaneous injection.
Companies competing with Apriligen for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Apriligen do?
- Apriligen develops autologous gene therapies for pediatric monogenic diseases, starting with Diamond Blackfan Anemia Syndrome. The company uses lentiviral technology to correct genetic defects by modifying patients' own cells, aiming to provide curative alternatives to traditional transplants.
- Who are Apriligen's investors?
- Apriligen's investors include Connecticut Innovations.